

May 17, 2022

**BSE Limited** Listing Department P J Towers, Dalal Street, Fort, Mumbai-400 001 **Scrip Code: 532321**  National Stock Exchange of India Limited Listing Department Exchange Plaza, 5th floor, Plot No. – C/1, G Block, Bandra-Kurla Complex, Bandra (E) Mumbai – 400 051 NSE Symbol: ZYDUSLIFE

Dear Sir / Madam,

## Re: <u>Prior intimation of the meeting of the Board of Directors in accordance with Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").</u>

This is further to our earlier letter dated May 13, 2022 intimating about the meeting of the Board of Directors of Zydus Lifesciences Limited ("**Company**") scheduled to be held on May 20, 2022.

In terms of regulation 29(1)(b) of the Listing Regulations, please note that the Board of Directors of the Company, at its aforesaid meeting, will also consider a proposal for buyback of fully paid-up equity shares of the Company and the matters necessary and incidental thereto, in accordance with the applicable provisions under the Companies Act, 2013 (including the rules and regulations framed thereunder), the Securities and Exchange Board of India (Buy-back of Securities) Regulations, 2018, as amended, and other applicable laws.

Kindly take the above on your record.

Thanking you,

For, **ZYDUS LIFESCIENCES LIMITED** 

DHAVAL SONI COMPANY SECRETARY & COMPLIANCE OFFICER



**Zydus Lifesciences Limited** (formerly known as Cadila Healthcare Limited)

**Regd. Office** : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000 website : www.zyduslife.com | CIN : L24230GJ1995PLC025878